# A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

> **NCT04784533** · PHASE2 · COMPLETED · sponsor: **Concert Pharmaceuticals** · enrollment: 317 (actual)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** CTP-543
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04784533
- **Lead sponsor:** Concert Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-26
- **Primary completion:** 2023-05-16
- **Final completion:** 2023-05-16
- **Target enrollment:** 317 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04784533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04784533, "A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04784533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*